# ENHANCE-2 (NCT04778397)

> Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04778397
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Gilead Sciences
- Conditions: Acute Myeloid Leukemia
- Interventions: Magrolimab; Venetoclax; Azacitidine; Cytarabine; Daunorubicin; Idarubicin; Steroidal Eye Drops
- Enrollment: 258
- Primary outcome: Overall Survival (OS) in Participants Appropriate for Non-intensive Therapy

## Commentary we found

- Podcasts: 7
- X threads: 5
- YouTube: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=enhance-2-nct04778397

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04778397", "email": "<work email>"}; the inbox owner confirms by the emailed link.